First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors

被引：2

作者：

Angevin, E. ^{[1
]}

Kelly, K. ^{[2
]}

Heist, R. ^{[3
]}

Morgensztern, D. ^{[4
]}

Weekes, C. ^{[5
]}

Bauer, T. M. ^{[6
]}

Ramanathan, R. K. ^{[7
]}

Nemunaitis, J. ^{[8
]}

Fan, X. ^{[9
]}

Olyaie, O. ^{[9
]}

Parikh, A. ^{[9
]}

Reilly, E. ^{[10
]}

Afar, D. ^{[9
]}

Naumovski, L. ^{[9
]}

Strickler, J. ^{[11
]}

机构：

[1] Gustave Roussy, Early Drug Dev Dept, Villejuif, France

[2] Univ Calif Davis, Ctr Comprehens Canc, Internal Med, Sacramento, CA 95817 USA

[3] Massachusetts Gen Hosp, Children Canc Ctr, Boston, MA 02114 USA

[4] Washington Univ, Sch Med, Oncol, St Louis, MO USA

[5] Univ Colorado, Dept Med, Ctr Canc, Anschutz Canc Pavil, Aurora, CO USA

[6] Tennessee Oncol, Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA

[7] Mayo Clin, Ctr Canc, Hematol Oncol, Phoenix, AZ USA

[8] Mary Crowley Canc Res Ctr, Oncol, Dallas, TX USA

[9] AbbVie, Biotherapeut, Redwood City, CA USA

[10] AbbVie Inc, Oncol, N Chicago, IL USA

[11] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw368.14

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

371P

引用

页数：1

共 50 条

[1] Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.
Strickler, John H.
Nemunaitis, John J.
Weekes, Colin D.
Ramanathan, Ramesh K.
Angevin, Eric
Morgensztern, Daniel
Heist, Rebecca Suk
Bauer, Todd Michael
Kaminker, Patrick
Fan, Xiaolin
Siggelkow, Sara
Wong, Shekman
Reilly, Edward B.
Afar, Daniel E.
Naumovski, Louie
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
Strickler, John H.
Weekes, Colin D.
Nemunaitis, John
Ramanathan, Ramesh K.
Heist, Rebecca S.
Morgensztern, Daniel
Angevin, Eric
Bauer, Todd M.
Yue, Huibin
Motwani, Monica
Parikh, Apurvasena
Reilly, Edward B.
Afar, Daniel
Naumovski, Louie
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (33) : 3298 - +
[3] First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC)
Angevin, Eric
Strickler, John
Weekes, Colin
Heist, Rebecca
Morgensztern, Daniel
Fan, Xiaolin
Olyaie, Ozzie
Motwani, Monica
Afar, Daniel
Naumovski, Louie
Kelly, Karen
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S395 - S396
[4] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Charlotte Lemech
Natasha Woodward
Nancy Chan
Joanne Mortimer
Louie Naumovski
Silpa Nuthalapati
Bo Tong
Fang Jiang
Peter Ansell
Christine K. Ratajczak
Jasgit Sachdev
Investigational New Drugs, 2020, 38 : 1815 - 1825
[5] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Lemech, Charlotte
Woodward, Natasha
Chan, Nancy
Mortimer, Joanne
Naumovski, Louie
Nuthalapati, Silpa
Tong, Bo
Jiang, Fang
Ansell, Peter
Ratajczak, Christine K.
Sachdev, Jasgit
INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1815 - 1825
[6] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors (vol 36, pg 3298, 2018)
Strickler, J. H.
Weekes, C. D.
Nemunaitis, J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 261 - 261
[7] Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors
Sharma, Manish
Kuboki, Yasutoshi
Camidge, D. Ross
Perets, Ruth
Sommerhalder, David
Yamamoto, Noboru
Bar, Jair
Parikh, Apurvasena
Li, Rui
Thiele, Gladys Morrison
Aristide, Martha Raluca Neagu
Freise, Kevin Jay
Powderly, John D.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
Angevin, Eric
Strickler, John H.
Weekes, Colin D.
Heist, Rebecca Suk
Morgensztern, Daniel
Nemunaitis, John J.
Fan, Xiaolin
Beaulieu, Juliette
Motwani, Monica
Afar, Daniel E.
Naumovski, Louie
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] First in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521
Kotecki, N.
van Herpen, C. M. L.
Curigliano, C.
Hendriks, M.
Vermaas, T. C.
Corrigan, L.
Belli, C.
Jungels, C.
Desar, I. M. E.
Koper, N. P.
Schellens, J. H. M.
Banerji, U.
CANCER RESEARCH, 2023, 83 (08)
[10] ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence
Wang, Jieyi
Anderson, Mark G.
Oleksijew, Anatol
Vaidya, Kedar S.
Boghaert, Erwin R.
Tucker, Lora
Zhang, Qian
Han, Edward K.
Palma, Joann P.
Naumovski, Louie
Reilly, Edward B.
CLINICAL CANCER RESEARCH, 2017, 23 (04) : 992 - 1000

← 1 2 3 4 5 →